The effect of MDR1 (P-gp) and ABCG2 on the drug resistance in Hep 2 cells.
- Author:
Zhenfeng SUN
;
Bin SHEN
;
Jia ZHANG
;
Tiantian SU
;
Pin DONG
- Publication Type:Journal Article
- MeSH:
ATP Binding Cassette Transporter, Subfamily B;
metabolism;
ATP Binding Cassette Transporter, Subfamily G, Member 2;
ATP-Binding Cassette Transporters;
metabolism;
Cell Line, Tumor;
Cisplatin;
pharmacology;
Doxorubicin;
pharmacology;
Drug Resistance, Neoplasm;
Humans;
Mitoxantrone;
pharmacology;
Neoplasm Proteins;
metabolism;
Paclitaxel;
pharmacology
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(11):1016-1019
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effect of MDR1 (P-gp) and ABCG2 on the drug resistance in Hep 2 cells.
METHOD:Flow cytometry was used to detect the variations of the antitumor drugs accumulation and discharging, and activity variations when MDR1 and ABCG2 inhibitors were used in Hep-2.
RESULT:The accumulation and discharging of mitoxantrone was significantly higher than the control group when ABCG2 inhibitor FTC was used in Hep-2 (P<0. 05). In contrast, P-gp did not appear similar case; To the mitoxantrone and cisplatin, there was no statistical correlation about activity of Hep-2 between P-gp or ABCG2 antagonist and the control; To the doxorubicin, combining FTC and P-gp, the activity of Hep-2 was higher than the control and difference was significant (P<. 05), In contrast, FTC and P-gp did not appear similar case when used alone; To the 5-FU, when PGP used, the activity of Hep-2 was higher than that in the control and difference was significant (P<0. 05), In con- trast, FTC and FTC+P-gp did not appear similar case; To the paclitaxel, when P-gp or FTC+P-gp used, the activity of Hep-2 was higher than that in the control and difference was significant(P<0. 05).
CONCLUSION:ABCG2 may lead to drug resistance mainly by changing the ability of cell in accumulating and discharging chemotherapy drugs. P-gp has other way. P-gp and ABCG2 play different roles in different drug resistance.
